KR20220093334A - Il-33 길항제의 이용 방법 - Google Patents

Il-33 길항제의 이용 방법 Download PDF

Info

Publication number
KR20220093334A
KR20220093334A KR1020227018052A KR20227018052A KR20220093334A KR 20220093334 A KR20220093334 A KR 20220093334A KR 1020227018052 A KR1020227018052 A KR 1020227018052A KR 20227018052 A KR20227018052 A KR 20227018052A KR 20220093334 A KR20220093334 A KR 20220093334A
Authority
KR
South Korea
Prior art keywords
antagonist
ser
egfr
abnormal
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227018052A
Other languages
English (en)
Korean (ko)
Inventor
라니아 대거
커스티 휴슬레이
마흐부베 가예디
샘 스트릭슨
엠마 수잔 코헨
마리아 벨비시
자비에 로메로 로스
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20220093334A publication Critical patent/KR20220093334A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227018052A 2019-11-04 2020-11-03 Il-33 길항제의 이용 방법 Ceased KR20220093334A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206984.7 2019-11-04
EP19206984 2019-11-04
PCT/EP2020/080841 WO2021089563A1 (en) 2019-11-04 2020-11-03 Methods of using il-33 antagonists

Publications (1)

Publication Number Publication Date
KR20220093334A true KR20220093334A (ko) 2022-07-05

Family

ID=68426347

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018052A Ceased KR20220093334A (ko) 2019-11-04 2020-11-03 Il-33 길항제의 이용 방법

Country Status (10)

Country Link
US (1) US20220380450A1 (cg-RX-API-DMAC10.html)
EP (1) EP4054711A1 (cg-RX-API-DMAC10.html)
JP (2) JP7843701B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220093334A (cg-RX-API-DMAC10.html)
CN (2) CN122140920A (cg-RX-API-DMAC10.html)
AU (2) AU2020379171B2 (cg-RX-API-DMAC10.html)
CA (1) CA3158323A1 (cg-RX-API-DMAC10.html)
IL (1) IL292443A (cg-RX-API-DMAC10.html)
TW (1) TW202134261A (cg-RX-API-DMAC10.html)
WO (1) WO2021089563A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991847T3 (es) 2021-08-27 2024-12-05 Medimmune Ltd Tratamiento de enfermedad pulmonar obstructiva crónica con un anticuerpo anti-interleucina-33
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素－３３抗體的氣喘治療

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
WO2015032932A1 (en) * 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック， インコーポレイテッド 抗インターロイキン−３３抗体及びその使用
MX387295B (es) * 2015-03-31 2025-03-18 Medimmune Ltd Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
SG11201808693WA (en) 2016-04-27 2018-11-29 Pfizer Anti-il-33 antibodies, compositions, methods and uses thereof
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
WO2018204598A1 (en) 2017-05-03 2018-11-08 The University Of North Carolina At Chapel Hill Methods for diagnosing or predicting chronic bronchitis

Also Published As

Publication number Publication date
US20220380450A1 (en) 2022-12-01
AU2020379171B2 (en) 2025-05-08
EP4054711A1 (en) 2022-09-14
AU2020379171A1 (en) 2022-06-09
IL292443A (en) 2022-06-01
JP2026012782A (ja) 2026-01-27
JP2023500492A (ja) 2023-01-06
JP7843701B2 (ja) 2026-04-10
AU2025213676A1 (en) 2025-08-28
CA3158323A1 (en) 2021-05-14
CN122140920A (zh) 2026-06-05
WO2021089563A1 (en) 2021-05-14
CN114901361A (zh) 2022-08-12
TW202134261A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
JP7079298B2 (ja) Ｗｎｔ経路関連疾患のための抗体および方法
JP2026012782A (ja) Ｉｌ－３３アンタゴニストの使用方法
US20250042986A1 (en) Stem cell factor inhibitor
US20220162322A1 (en) Anti bdca-2 antibodies
AU2017283787A1 (en) Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
TW201818957A (zh) Ｉｌ－８相關疾病之治療用或預防用組成物
Beidler et al. Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-α and epiregulin
EP3847192A1 (en) Monoclonal antibodies against endotrophin and the use thereof
EA052516B1 (ru) Способы применения антагонистов il-33
KR20220092927A (ko) 신장 장애를 치료하기 위한 항 il-33 치료제

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601